Berzosertib, also known as VE-822 and VX-970, is an potent ATR inhibitor. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity. These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC..
MedKoo Cat#: 406258
Name: Berzosertib
CAS#: 1232416-25-9
Chemical Formula: C24H25N5O3S
Exact Mass: 463.1678
Molecular Weight: 463.55
Elemental Analysis: C, 62.18; H, 5.44; N, 15.11; O, 10.35; S, 6.92
| Solvent | mg/mL | mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 40.0 | 86.29 | |
| Water | 0.0 | 0.00 |
The following data is based on the product molecular weight 463.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
